logo
logo
BrainsWay Ltd.

BrainsWay Ltd.

NASDAQ•BWAY
CEO: Mr. Hadar Levy
セクター: Healthcare
業種: Medical - Devices
上場日: 2019-04-17
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
連絡先情報
Bynet Building, 3rd Floor 19 Hartum Street Har Hotzvim, Jerusalem, 9777518, Israel
972-2-582-4030
www.brainsway.com
時価総額
$504.48M
PER (TTM)
73.4
29.9
配当利回り
--
52週高値
$25.65
52週安値
$7.84
52週レンジ
96%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$13.51M+28.66%
直近4四半期の推移

EPS

$0.08+0.00%
直近4四半期の推移

フリーCF

$586.00K-40.08%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Revenue Jumps 29% Total revenues reached $41.0M in 2024, marking a 29% increase driven by higher system sales and leases.
Achieved Net Profitability Company achieved net income of $2.9M in 2024, reversing the $(4.2M) net loss reported in the prior year.
Operating Cash Flow Strong Net cash provided by operating activities was $10.3M for 2024, significantly up from $1.3M in 2023.
Secured $20M Financing Consummated private placement with Valor in November 2024, securing aggregate gross proceeds of approximately $20M.

リスク要因

Future Profitability Uncertain History of operating losses persists; management cannot ensure existing capital suffices for future requirements or sustained profitability.
Geopolitical Supply Chain Risks Geopolitical instability, including regional conflicts, causes supply chain disruptions, increased shipping costs, and operational uncertainty.
Market Acceptance Critical Success depends entirely on market perception and acceptance of Deep TMS technology as a safe and effective treatment option.
Clinical Trials Uncertainty Developing new indications requires lengthy, expensive clinical trials with uncertain outcomes, potentially delaying commercialization.

見通し

Focus on Core Commercialization Strategy centers on scaling full commercialization for MDD, OCD, and smoking addiction, focusing heavily on the large US market.
Advance Next-Gen Technology Actively developing next-generation multichannel device utilizing patented rotational field TMS technology for broader stimulation.
Pursue New Indications Intends to conduct clinical trials for additional psychiatric, neurological, and addiction disorders presenting promising market opportunities.
Increase International Footprint Working to expand commercial footprint across Europe, Asia, Latin America, and the Middle East via distributors and agents.

同業比較

売上高 (TTM)

Tactile Systems Technology, Inc.TCMD
$329.52M
+12.5%
Viemed Healthcare, Inc.VMD
$254.79M
+18.9%
Cerus CorporationCERS
$199.19M
+13.0%

粗利益率 (最新四半期)

Delcath Systems, Inc.DCTH
87.2%
+1.9pp
Sight Sciences, Inc.SGHT
86.4%
+2.5pp
CVRx, Inc.CVRX
86.3%
+3.6pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TCMD$626.51M32.99.3%5.8%
NPCE$515.60M-21.4-136.6%66.4%
BWAY$504.48M73.49.5%6.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
5.8%
安定成長
4四半期純利益CAGR
0.4%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年3月10日
|
EPS:$0.11
|
売上高:$14.02M
財務レポート
財務データ
ニュース
全年度

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年4月22日|
    売上高: $41.02M+29.0%
    |
    EPS: $0.17+166.2%
    予想を上回る

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月28日|
    売上高: $31.79M+17.0%
    |
    EPS: $-0.26+69.8%
    予想を下回る

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月27日|
    売上高: $27.18M-8.4%
    |
    EPS: $-0.86-104.8%
    予想を下回る

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年4月12日|
    売上高: $29.66M+34.5%
    |
    EPS: $-0.42+12.5%
    予想を下回る

  • Form 20-F/A - FY 2020

    会計期末: 2020年12月31日|提出日: 2021年6月17日|
    売上高: $22.06M-4.5%
    |
    EPS: $-0.48+52.0%
    予想を下回る

  • Form 20-F - FY 2020

    会計期末: 2020年12月31日|提出日: 2021年4月19日|修正版データを参照